Floatz Rating
BB65/100
Confidence
Indicative
Sponsor
University of Utah
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
60High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06390956CT.gov Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL) | — | Recruiting | — | — | — |
NCT05990465CT.gov LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies | — | Recruiting | — | — | — |
NCT05024045CT.gov Study of Oral LOXO-338 in Patients With Advanced Blood Cancers | — | Active Not Recruiting | — | — | — |
NCT04849416CT.gov A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia) | — | Completed | — | — | — |
NCT03740529CT.gov A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Marginal Zone Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Pirtobrutinib (this asset) | University of Utah | P2 | BB · 65 |
| Etoposide | University of Miami | P2 | BBB |
| Orelabrutinib | Henan Cancer Hospital | P4 | BBB |
| Vincristine Sulfate | Mayo Clinic | P2 | BBB |
| Cyclosporin A | Fred Hutchinson Cancer Center | P2 | BBB |
| Nivestim | Fred Hutchinson Cancer Center | P2 | BBB |
| Irinotecan | National Cancer Institute (NCI) | P2 | BB |
| Romidepsin | City of Hope Medical Center | P2 | BB |
| Fludarabine | Paolo Caimi, MD | P2 | BB |
+42 more in the Marginal Zone Lymphoma cohort
Other indications for Pirtobrutinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | — | P4 | BB · 68 |
| B-Cell Non-Hodgkin Lymphoma | — | P3 | BB · 68 |
| Non-Hodgkin Lymphoma | — | P4 | BB · 67 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Pirtobrutinib in Marginal Zone Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/pirtobrutinib-marginal-zone-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →